H
Hong Liu
Researcher at Shandong University
Publications - 2349
Citations - 79103
Hong Liu is an academic researcher from Shandong University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 100, co-authored 1905 publications receiving 57561 citations. Previous affiliations of Hong Liu include Shanghai University & Guangzhou University.
Papers
More filters
Journal ArticleDOI
Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011).
Jiang Wang,María Sánchez-Roselló,José Luis Aceña,Carlos del Pozo,Alexander E. Sorochinsky,Alexander E. Sorochinsky,Alexander E. Sorochinsky,Santos Fustero,Vadim A. Soloshonok,Vadim A. Soloshonok,Hong Liu +10 more
TL;DR: Introduced to the Market in the Last Decade (2001−2011) Jiang Wang,† María Sańchez-Rosello,́‡,§ Jose ́ Luis Aceña, Carlos del Pozo,‡ and Hong Liu.
Journal ArticleDOI
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin,Zhenming Jin,Xiaoyu Du,Yechun Xu,Yong-Qiang Deng,Meiqin Liu,Yao Zhao,Bing Zhang,Xiaofeng Li,Leike Zhang,Chao Peng,Yinkai Duan,Jing Yu,Lin Wang,Kailin Yang,Fengjiang Liu,Ren-Di Jiang,Xing-Lou Yang,Tian You,Liu X,Xiuna Yang,Fang Bai,Hong Liu,Xiang Liu,Luke W. Guddat,Wenqing Xu,Wenqing Xu,Gengfu Xiao,Cheng-Feng Qin,Zhengli Shi,Hualiang Jiang,Hualiang Jiang,Zihe Rao,Zihe Rao,Zihe Rao,Haitao Yang +35 more
TL;DR: A programme of structure-assisted drug design and high-throughput screening identifies six compounds that inhibit the main protease of SARS-CoV-2, demonstrating the ability of this strategy to isolate drug leads with clinical potential.
Journal ArticleDOI
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
Yu Zhou,Jiang Wang,Zhanni Gu,Shuni Wang,Wei Zhu,José Luis Aceña,Vadim A. Soloshonok,Kunisuke Izawa,Hong Liu +8 more
TL;DR: Compounds Currently in Phase II−III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas is presented.
Journal ArticleDOI
Applications of 2D MXenes in energy conversion and storage systems
Jinbo Pang,Rafael G. Mendes,Rafael G. Mendes,Alicja Bachmatiuk,Alicja Bachmatiuk,Alicja Bachmatiuk,Liang Zhao,Huy Q. Ta,Thomas Gemming,Hong Liu,Hong Liu,Zhongfan Liu,Zhongfan Liu,Mark H. Rümmeli,Mark H. Rümmeli,Mark H. Rümmeli +15 more
TL;DR: The potential of MXenes for the photocatalytic degradation of organic pollutants in water, such as dye waste, is addressed, along with their promise as catalysts for ammonium synthesis from nitrogen.
Journal ArticleDOI
Synthesis of Few-Layer MoS2 Nanosheet-Coated TiO2 Nanobelt Heterostructures for Enhanced Photocatalytic Activities
Weijia Zhou,Zongyou Yin,Yaping Du,Xiao Huang,Zhiyuan Zeng,Zhanxi Fan,Hong Liu,Jiyang Wang,Hua Zhang +8 more
TL;DR: The as-prepared TiO( 2)@MoS(2) heterostructure shows a high photocatalytic hydrogen production even without the Pt co-catalyst and possesses a strong adsorption ability towards organic dyes and shows high performance in photocatallytic degradation of the dye molecules.